Uniqure NV Company Profile (NASDAQ:QURE)

About Uniqure NV

Uniqure NV logouniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. Its product candidates include AMT-060 for Hemophilia B, AMT-110 for Sanfilippo B Syndrome, AAV2/GDNF for Parkinson's Disease, S100A1 for Congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). For the AMT-060, the Company is conducting a Phase I/II clinical trial. The AMT-110 is based on glial cell line-derived neurotrophic factor, which is being studied in an investigator-sponsored Phase I clinical study. The AMT-130 is used for the treatment of Huntington's disease, in which the Company has demonstrated preclinical proof of concept.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: QURE
  • CUSIP:
Key Metrics:
  • Previous Close: $6.14
  • 50 Day Moving Average: $5.98
  • 200 Day Moving Average: $6.91
  • 52-Week Range: $5.25 - $15.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.45
  • P/E Growth: 0.00
  • Market Cap: $154.34M
  • Outstanding Shares: 25,136,000
  • Beta: 0.15
Profitability:
  • Net Margins: -370.57%
  • Return on Equity: -70.75%
  • Return on Assets: -30.99%
Debt:
  • Debt-to-Equity Ratio: 0.25%
  • Current Ratio: 7.34%
  • Quick Ratio: 7.33%
Additional Links:
Companies Related to Uniqure NV:

Analyst Ratings

Consensus Ratings for Uniqure NV (NASDAQ:QURE) (?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $16.57 (169.89% upside)

Analysts' Ratings History for Uniqure NV (NASDAQ:QURE)
Show:
DateFirmActionRatingPrice TargetDetails
1/30/2017Chardan CapitalReiterated RatingPositive$12.00View Rating Details
12/25/2016Oppenheimer Holdings, Inc.Set Price TargetBuy$17.00View Rating Details
12/2/2016Leerink SwannReiterated RatingOutperformView Rating Details
12/6/2016WallachBeth CapitalLower Price TargetBuy$27.00 -> $15.00View Rating Details
11/28/2016Jefferies Group LLCDowngradeBuy -> Hold$28.00 -> $8.00View Rating Details
11/15/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralView Rating Details
8/4/2016HC WainwrightInitiated CoverageBuy$21.00View Rating Details
7/28/2016Cowen and CompanyReiterated RatingBuyView Rating Details
1/8/2016Janney Montgomery ScottReiterated RatingBuyView Rating Details
1/8/2016Roth CapitalReiterated RatingBuy$37.00View Rating Details
5/9/2015BMO Capital MarketsReiterated RatingOutperform -> PositiveView Rating Details
(Data available from 2/28/2015 forward)

Earnings

Earnings History for Uniqure NV (NASDAQ:QURE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/3/2017        
5/31/2016Q1($0.82)($0.93)ViewN/AView Earnings Details
4/4/2016Q415($0.60)($0.58)ViewN/AView Earnings Details
11/30/2015Q315($0.64)($1.14)ViewListenView Earnings Details
8/27/2015Q215($0.56)($0.98)ViewN/AView Earnings Details
6/11/2015Q1($0.82)($0.69)$9.50 million$1.17 millionViewN/AView Earnings Details
4/6/2015($0.62)($0.77)ViewN/AView Earnings Details
12/1/2014($0.53)($0.61)$2.00 million$1.30 millionViewN/AView Earnings Details
9/2/2014Q214($0.55)($1.35)ViewN/AView Earnings Details
6/6/2014($0.45)($0.52)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Uniqure NV (NASDAQ:QURE)
Current Year EPS Consensus Estimate: $-2.89 EPS
Next Year EPS Consensus Estimate: $-2.51 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.94)($0.63)($0.75)
Q2 20163($0.98)($0.74)($0.85)
Q3 20163($0.96)($0.61)($0.81)
Q4 20163($0.99)($0.48)($0.73)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Uniqure NV (NASDAQ:QURE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Uniqure NV (NASDAQ:QURE)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Uniqure NV (NASDAQ:QURE)
DateHeadline
News IconWhat Are the Technicals Saying About These Shares: Uniqure NV (QURE) - Providence Standard (NASDAQ:QURE)
providencestandard.com - February 27 at 4:17 PM
News IconMarket Review: Indicator Watch for Uniqure NV (QURE) - Davidson Register (NASDAQ:QURE)
davidsonregister.com - February 24 at 8:41 PM
News IconStock Chatter: uniQure N.V. (NASDAQ:QURE) Price Target Update ... - Rockville Register (NASDAQ:QURE)
rockvilleregister.com - February 24 at 8:41 PM
News IconStock Levels in Review for Uniqure NV (QURE) - Baxter Review (NASDAQ:QURE)
baxternewsreview.com - February 24 at 8:12 AM
News IconChecking Indicator Levels for Uniqure NV (QURE) - Rives Journal (NASDAQ:QURE)
rivesjournal.com - February 22 at 7:37 PM
News IconErratic Volume Stretches This Stock Mid-Session: uniQure NV (NASDAQ:QURE) - Aiken Advocate (NASDAQ:QURE)
aikenadvocate.com - February 22 at 7:37 PM
investornewswire.com logouniQure N.V. (NASDAQ:QURE) EPS Target At $-0.44 - Investor Newswire (NASDAQ:QURE)
www.investornewswire.com - February 22 at 9:30 AM
News IconAnalysts Peer Into Their Crystal Balls For uniQure NV (NASDAQ:QURE): Where Is It headed? - Winfield Review (NASDAQ:QURE)
winfieldreview.com - February 22 at 9:30 AM
News IconUniQure NV QURE Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:QURE)
www.bioportfolio.com - February 19 at 6:26 PM
News IconSteering Attention Towards Earnings; Analysts Weigh in on uniQure ... - Aiken Advocate (NASDAQ:QURE)
aikenadvocate.com - February 18 at 8:12 AM
finance.yahoo.com logoCan The Uptrend Continue for uniQure N.V. (QURE)? (NASDAQ:QURE)
finance.yahoo.com - February 15 at 12:16 AM
finance.yahoo.com logoWill Uniqure (QURE) Continue to Surge Higher? (NASDAQ:QURE)
finance.yahoo.com - February 10 at 10:09 PM
News IconWhat’s Propelling Uniqure NV (QURE) to Decrease? The Stock Formed a Bearish Wedge Down Chart Pattern (NASDAQ:QURE)
randolphguide.com - February 3 at 9:54 PM
marketexclusive.com logouniQure N.V. (NASDAQ:QURE) Files An 8-K Other Events - Market Exclusive (NASDAQ:QURE)
marketexclusive.com - January 31 at 9:29 PM
News IconLuxury Writing Instruments and Stationery in the United Arab Emirates - New Study Released (NASDAQ:QURE)
reports.pr-inside.com - January 30 at 8:08 PM
News IconA.M. Best Announces New Database of Solvency and Financial Condition Report Filings: Best’s Statement File – Solvency II (NASDAQ:QURE)
www.pr-inside.com - January 30 at 8:08 PM
4-traders.com logoGlobal Fuel Cell Market Analysis & Trends - Industry Forecast to 2025 - Expected to Reach $12.5 Billion - Research and Markets (NASDAQ:QURE)
www.4-traders.com - January 30 at 8:08 PM
streetinsider.com logouniQure (QURE) AMT-060 Granted FDA Breakthrough Therapy Designation (NASDAQ:QURE)
www.streetinsider.com - January 30 at 8:08 PM
us.rd.yahoo.com logouniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B (NASDAQ:QURE)
us.rd.yahoo.com - January 30 at 8:08 PM
streetinsider.com logouniQure (QURE) AMT-060 Granted FDA Breakthrough Therapy Designation - StreetInsider.com (NASDAQ:QURE)
www.streetinsider.com - January 30 at 8:08 AM
News IconEarnings in Full Force, Analysts Take Aim at uniQure N.V. (NASDAQ:QURE) - Wall Street Beacon (NASDAQ:QURE)
wsbeacon.com - January 28 at 6:05 AM
News IconHuntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016 - New Study Released (NASDAQ:QURE)
reports.pr-inside.com - January 26 at 2:31 AM
finance.yahoo.com logouniQure Appoints Alexander Kuta as Senior Vice President of Regulatory Affairs (NASDAQ:QURE)
finance.yahoo.com - January 26 at 2:31 AM
News IconSharp Decline Puts This Stock at a New Low: uniQure N.V. ... - Wall Street Beacon (NASDAQ:QURE)
wsbeacon.com - January 25 at 1:17 AM
News IconUniQure NV QURE Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:QURE)
www.bioportfolio.com - January 20 at 6:26 AM
News IconWill The Needle Move For uniQure N.V. (NASDAQ:QURE) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:QURE)
wsbeacon.com - January 14 at 5:20 AM
investornewswire.com logoSentiments And Ratings Alert: uniQure N.V. (NASDAQ:QURE) - Investor Newswire (NASDAQ:QURE)
www.investornewswire.com - January 12 at 1:13 AM
finance.yahoo.com logouniQure Outlines Key Initiatives for 2017 and Vision for 2018 (NASDAQ:QURE)
finance.yahoo.com - January 9 at 8:08 PM
streetinsider.com logoForm 3 uniQure NV For: Jan 01 Filed by: Cantor Maria E - StreetInsider.com (NASDAQ:QURE)
www.streetinsider.com - January 6 at 5:53 AM
finance.yahoo.com logouniQure (QURE): Strong Industry, Solid Earnings Estimate Revisions (NASDAQ:QURE)
finance.yahoo.com - December 29 at 7:25 PM
News IconUpside Alert: Delving into Shares of uniQure N.V. (NASDAQ:QURE) - Prospect Journal (NASDAQ:QURE)
prospectjournal.com - December 27 at 9:33 AM
stocksdaily.net logouniQure NV (NASDAQ:QURE) EPS Projection At $-0.62? - Stocks Daily (NASDAQ:QURE)
www.stocksdaily.net - December 27 at 9:33 AM
reuters.com logoBRIEF-Uniqure appoints Matthew Kapusta as chief executive officer (NASDAQ:QURE)
www.reuters.com - December 21 at 12:07 AM
us.rd.yahoo.com logouniQure Appoints Matthew Kapusta as Chief Executive Officer (NASDAQ:QURE)
us.rd.yahoo.com - December 21 at 12:07 AM
us.rd.yahoo.com logo7:14 am uniQure appoints interim CEO and CFO Matthew Kapusta as CEO; will conduct search for new CFO effective immediately (NASDAQ:QURE)
us.rd.yahoo.com - December 21 at 12:07 AM
News IconTop Stock With Upside & Growth Potential: uniQure N.V. (NASDAQ:QURE) - Prospect Journal (NASDAQ:QURE)
prospectjournal.com - December 20 at 2:04 PM
globenewswire.com logouniQure Appoints Matthew Kapusta as Chief Executive Officer - GlobeNewswire (press release) (NASDAQ:QURE)
globenewswire.com - December 20 at 2:04 PM
streetinsider.com logoForm 6-K uniQure NV For: Dec 19 - StreetInsider.com (NASDAQ:QURE)
www.streetinsider.com - December 19 at 8:17 AM
News IconHuntington Disease Pipeline Market Review And Therapeutics Development H2 2016 (NASDAQ:QURE)
www.free-press-release-center.info - December 18 at 8:01 AM
insidermonkey.com logoWhat Hedge Funds Think About Uniqure NV (QURE)? - Insider Monkey (blog) (NASDAQ:QURE)
www.insidermonkey.com - December 16 at 3:23 AM
seekingalpha.com logoUniQure settles arbitration case for €2.7M - Seeking Alpha (NASDAQ:QURE)
seekingalpha.com - December 16 at 3:23 AM
insidermonkey.com logoWhat Hedge Funds Think About Uniqure NV (QURE)? (NASDAQ:QURE)
www.insidermonkey.com - December 15 at 10:21 PM
News IconEditing set to broaden genetic blood fixes (NASDAQ:QURE)
www.bioworld.com - December 6 at 9:06 AM
us.rd.yahoo.com logoHere’s Why We Think There’s Opportunity In Uniqure NV (QURE) (NASDAQ:QURE)
us.rd.yahoo.com - December 5 at 7:21 PM
marketexclusive.com logoHere’s Why We Think There’s Opportunity In Uniqure NV (NASDAQ:QURE) (NASDAQ:QURE)
marketexclusive.com - December 5 at 9:32 AM
finance.yahoo.com logo2:03 am uniQure reports first clinical data from second dose cohort of AMT-060; demonstrates dose response with all patients free of prophylactic FIX replacement therapy (NASDAQ:QURE)
finance.yahoo.com - December 5 at 9:32 AM
globenewswire.com logouniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients ... - GlobeNewswire (press release) (NASDAQ:QURE)
globenewswire.com - December 3 at 6:32 PM
einnews.com logouniQure to Present at the Genetic Rx Boston Biotech Conference at Harvard Medical School - EIN News (press release) (NASDAQ:QURE)
www.einnews.com - December 2 at 11:59 AM
finance.yahoo.com logouniQure to Present at the Genetic Rx Boston Biotech Conference at Harvard Medical School (NASDAQ:QURE)
finance.yahoo.com - December 2 at 11:59 AM
marketexclusive.com logoJefferies Group has upgraded the stock of Gap Inc. (NYSE:GPS) (NASDAQ:QURE)
marketexclusive.com - November 29 at 1:55 PM

Social

What is Uniqure NV's stock symbol?

Uniqure NV trades on the NASDAQ under the ticker symbol "QURE."

Where is Uniqure NV's stock going? Where will Uniqure NV's stock price be in 2017?

8 brokers have issued 1-year price targets for Uniqure NV's stock. Their forecasts range from $8.00 to $27.00. On average, they expect Uniqure NV's share price to reach $16.57 in the next twelve months.

When will Uniqure NV announce their earnings?

Uniqure NV is scheduled to release their next quarterly earnings announcement on Monday, April, 3rd 2017.

Who owns Uniqure NV stock?

Uniqure NV's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (5.04%), FMR LLC (4.68%), Putnam Investments LLC (1.30%), City Financial Investment Co Ltd (1.06%), Renaissance Technologies LLC (1.00%) and FT Options LLC (0.26%).

Who sold Uniqure NV stock? Who is selling Uniqure NV stock?

Uniqure NV's stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC.

Who bought Uniqure NV stock? Who is buying Uniqure NV stock?

Uniqure NV's stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, City Financial Investment Co Ltd, FMR LLC, FT Options LLC, Commonwealth of Pennsylvania Public School Empls Retrmt SYS and Renaissance Technologies LLC.

How do I buy Uniqure NV stock?

Shares of Uniqure NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Uniqure NV stock cost?

One share of Uniqure NV stock can currently be purchased for approximately $6.14.

Uniqure NV (NASDAQ:QURE) Chart for Tuesday, February, 28, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Uniqure NV (NASDAQ:QURE)

Earnings History Chart

Earnings by Quarter for Uniqure NV (NASDAQ:QURE)

Dividend History Chart

Dividend Payments by Quarter for Uniqure NV (NASDAQ:QURE)

Last Updated on 2/28/2017 by MarketBeat.com Staff